Autoimmune Pulmonary Alveolar Proteinosis clinical trials at University of California Health
1 in progress, 0 open to eligible people
Sorry, in progress, not accepting new patients
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.